Dennis J. Slamon

100.1k total citations · 27 hit papers
417 papers, 65.5k citations indexed

About

Dennis J. Slamon is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dennis J. Slamon has authored 417 papers receiving a total of 65.5k indexed citations (citations by other indexed papers that have themselves been cited), including 277 papers in Oncology, 141 papers in Molecular Biology and 133 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dennis J. Slamon's work include HER2/EGFR in Cancer Research (174 papers), Advanced Breast Cancer Therapies (95 papers) and Monoclonal and Polyclonal Antibodies Research (87 papers). Dennis J. Slamon is often cited by papers focused on HER2/EGFR in Cancer Research (174 papers), Advanced Breast Cancer Therapies (95 papers) and Monoclonal and Polyclonal Antibodies Research (87 papers). Dennis J. Slamon collaborates with scholars based in United States, Germany and Canada. Dennis J. Slamon's co-authors include Axel Ullrich, Steven Wong, Wendy J. Levin, Gary M. Clark, William McGuire, Mark D. Pegram, Michael F. Press, Steven Shak, Janet Wolter and Virginia Paton and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Dennis J. Slamon

409 papers receiving 63.7k citations

Hit Papers

Human Breast Cancer: Corr... 1982 2026 1996 2011 1987 2001 1989 1999 2016 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene
    1987 9.3k citations Dennis J. Slamon et al. profile →
  2. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
    2001 8.4k citations Dennis J. Slamon, Mark D. Pegram et al. profile →
  3. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
    1989 5.7k citations Dennis J. Slamon, Michael F. Press et al. profile →
  4. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
    1999 2.2k citations Dennis J. Slamon et al. Journal of Clinical Oncology profile →
  5. Palbociclib and Letrozole in Advanced Breast Cancer
    2016 1.9k citations Richard S. Finn, Miguel Martín et al. profile →
  6. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
    2002 1.5k citations Dennis J. Slamon, Michael F. Press et al. Journal of Clinical Oncology profile →
  7. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
    2014 1.4k citations Richard S. Finn, John Crown et al. profile →
  8. Expression of a multidrug-resistance gene in human tumors and tissues.
    1987 1.3k citations Dennis J. Slamon et al. profile →
  9. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
    2016 1.2k citations Dennis J. Slamon et al. profile →
  10. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    2009 1.0k citations Richard S. Finn, Judy Dering et al. Breast Cancer Research profile →
  11. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
    2010 923 citations Dennis J. Slamon, Victor E. Velculescu et al. profile →
  12. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
    1998 848 citations Mark D. Pegram, D L Baly et al. Journal of Clinical Oncology profile →
  13. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
    2018 777 citations Dennis J. Slamon, Fabrice André et al. profile →
  14. Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
    2006 711 citations Gottfried E. Konecny, Mark D. Pegram et al. profile →
  15. Expression of Cellular Oncogenes in Human Malignancies
    1984 696 citations Dennis J. Slamon et al. profile →
  16. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    1997 643 citations Michael F. Press, Dennis J. Slamon et al. Journal of Clinical Oncology profile →
  17. Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry
    2000 576 citations Dennis J. Slamon et al. Journal of Clinical Oncology profile →
  18. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
    1999 540 citations Mark D. Pegram, Gail D. Lewis Phillips et al. Oncogene profile →
  19. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
    1990 531 citations Michael F. Press, Dennis J. Slamon et al. profile →
  20. Prognostic classification of breast ductal carcinoma-in-situ
    1995 503 citations Dennis J. Slamon et al. profile →
  21. Differential expression of cellular oncogenes during pre- and postnatal development of the mouse
    1982 480 citations Dennis J. Slamon et al. profile →
  22. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
    2017 337 citations Sara A. Hurvitz, Miguel Martín et al. profile →
  23. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
    2019 286 citations Richard S. Finn, Dennis J. Slamon et al. profile →
  24. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
    2021 161 citations Dennis J. Slamon, Guy Jérusalem et al. Annals of Oncology profile →
  25. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
    2022 114 citations Dennis J. Slamon, Fabrice André et al. Clinical Cancer Research profile →
  26. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
    2022 109 citations Richard S. Finn, Miguel Martín et al. Journal of Clinical Oncology profile →
  27. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
    2024 81 citations Dennis J. Slamon, Miguel Martín et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dennis J. Slamon United States 103 45.1k 23.5k 18.7k 15.8k 13.9k 417 65.5k
José Baselga Spain 94 34.9k 0.8× 17.3k 0.7× 12.4k 0.7× 13.6k 0.9× 9.4k 0.7× 273 49.5k
José Baselga United States 98 25.8k 0.6× 19.7k 0.8× 6.3k 0.3× 14.1k 0.9× 9.8k 0.7× 484 46.7k
Mien‐Chie Hung United States 138 28.0k 0.6× 43.4k 1.8× 6.7k 0.4× 7.7k 0.5× 13.8k 1.0× 745 67.2k
Johann S. de Bono United Kingdom 108 22.3k 0.5× 18.9k 0.8× 9.9k 0.5× 29.0k 1.8× 14.1k 1.0× 1.0k 53.2k
Martine Piccart Belgium 102 27.4k 0.6× 12.8k 0.5× 5.0k 0.3× 9.2k 0.6× 16.4k 1.2× 836 42.9k
Axel Ullrich Germany 97 23.0k 0.5× 32.2k 1.4× 11.9k 0.6× 4.3k 0.3× 6.8k 0.5× 257 55.6k
Hope S. Rugo United States 90 31.3k 0.7× 11.2k 0.5× 3.9k 0.2× 16.6k 1.1× 11.5k 0.8× 847 45.2k
Gary M. Clark United States 79 28.3k 0.6× 14.0k 0.6× 7.1k 0.4× 10.6k 0.7× 14.5k 1.0× 274 44.5k
Carlos Cordon‐Cardo United States 129 22.8k 0.5× 41.4k 1.8× 5.0k 0.3× 11.0k 0.7× 12.8k 0.9× 564 68.1k
Daniel F. Hayes United States 95 27.3k 0.6× 13.3k 0.6× 6.0k 0.3× 9.7k 0.6× 21.8k 1.6× 412 47.9k

Countries citing papers authored by Dennis J. Slamon

Since Specialization
Citations

This map shows the geographic impact of Dennis J. Slamon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis J. Slamon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis J. Slamon more than expected).

Fields of papers citing papers by Dennis J. Slamon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis J. Slamon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis J. Slamon. The network helps show where Dennis J. Slamon may publish in the future.

Co-authorship network of co-authors of Dennis J. Slamon

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis J. Slamon. A scholar is included among the top collaborators of Dennis J. Slamon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis J. Slamon. Dennis J. Slamon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hurvitz, Sara A., Nicholas P. McAndrew, Aditya Bardia, et al.. (2021). A careful reassessment of anthracycline use in curable breast cancer. npj Breast Cancer. 7(1). 134–134. 33 indexed citations
2.
Peddi, Parvin F. & Dennis J. Slamon. (2020). Frontiers in HER2-positive breast cancer in 2020. Current Opinion in Obstetrics & Gynecology. 33(1). 48–52. 2 indexed citations
3.
Hurvitz, Sara A., Miguel Martín, Michael F. Press, et al.. (2019). Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer. Clinical Cancer Research. 26(3). 566–580. 154 indexed citations
4.
Hu‐Lieskovan, Siwen, Aaron Lisberg, Jesse M. Zaretsky, et al.. (2019). Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(16). 5061–5068. 56 indexed citations
5.
O’Brien, Neil A., Dylan Conklin, Richard P. Beckmann, et al.. (2018). Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics. 17(5). 897–907. 80 indexed citations
6.
André, Fabrice, Sara A. Hurvitz, Angelica Fasolo, et al.. (2016). Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology. 34(18). 2115–2124. 135 indexed citations
7.
Beltran, Pedro J., Frank J. Calzone, Petia Mitchell, et al.. (2014). Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. Clinical Cancer Research. 20(11). 2947–2958. 41 indexed citations
8.
Wainberg, Zev A., Adrian Anghel, Amrita Desai, et al.. (2013). Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer. Molecular Cancer Therapeutics. 12(4). 509–519. 58 indexed citations
9.
Garon, Edward B., Richard J. Pietras, Richard S. Finn, et al.. (2013). Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(3). 270–278. 47 indexed citations
10.
O’Brien, Neil A., Brigid C. Browne, Lucy Chow, et al.. (2010). Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib. Molecular Cancer Therapeutics. 9(6). 1489–1502. 249 indexed citations
11.
Browne, Brigid C., John Crown, Natarajan Venkatesan, et al.. (2010). Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Annals of Oncology. 22(1). 68–73. 84 indexed citations
12.
Wu, Yanyuan, et al.. (2008). Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Research. 10(1). R3–R3. 45 indexed citations
13.
Wilson, Cindy, Elaina Cajulis, Jennifer L. Green, et al.. (2005). HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Research. 7(6). R1058–79. 45 indexed citations
14.
Pegram, Mark D., G. Konecny, Christopher J. O’Callaghan, et al.. (2004). Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. JNCI Journal of the National Cancer Institute. 96(10). 739–749. 395 indexed citations
15.
Konecny, Gottfried E., Y. Gloria Meng, Michael Untch, et al.. (2004). Association between HER-2/ neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients. Clinical Cancer Research. 10(5). 1706–1716. 230 indexed citations
16.
Chan, Kai Chio, W.F. Knox, Ashu Gandhi, et al.. (2001). Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. British journal of surgery. 88(3). 412–418. 50 indexed citations
17.
Pegram, Mark D., Gail D. Lewis Phillips, Richard J. Pietras, et al.. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 18(13). 2241–2251. 540 indexed citations breakdown →
18.
Landgraf, Ralf, Mark D. Pegram, Dennis J. Slamon, & David Eisenberg. (1998). Cytotoxicity and Specificity of Directed Toxins Composed of Diphtheria Toxin and the EGF-like Domain of Heregulin β1. Biochemistry. 37(9). 3220–3228. 11 indexed citations
19.
Reese, David & Dennis J. Slamon. (1997). HER‐2/ neu Signal Transduction in Human Breast and Ovarian Cancer. Stem Cells. 15(1). 1–8. 192 indexed citations
20.
Aboulafia, David M., Ronald T. Mitsuyasu, & Dennis J. Slamon. (1991). Human T-Cell Leukemia Virus Infection in Non-Intravenous Drug Using HIV Seropositive Men in Los Angeles. AIDS Research and Human Retroviruses. 7(3). 333–336. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by Mien‐Chie Hung Breakdown of academic impact, for papers by Johann S. de Bono Breakdown of academic impact, for papers by Martine Piccart Breakdown of academic impact, for papers by Axel Ullrich Breakdown of academic impact, for papers by Hope S. Rugo Breakdown of academic impact, for papers by Gary M. Clark Breakdown of academic impact, for papers by Carlos Cordon‐Cardo Breakdown of academic impact, for papers by Daniel F. Hayes
Rankless by CCL
2026